Lupin Secures Exclusive India Deal for Diabetes-Weight Loss Drug bofanglutide

• Lupin partners with China's Gan & Lee for exclusive India rights to bofanglutide.
• bofanglutide is a novel fortnightly GLP-1 receptor agonist for type 2 diabetes and weight management.
• The drug offers convenient fortnightly dosing with comparable or better weight loss than weekly alternatives.
• Aims to strengthen Lupin's diabetes portfolio and expand its presence in the obesity segment in India.
• India faces significant challenges with 90 million adults affected by diabetes and 50 million by obesity.

Why It Matters: Lupin's new deal for bofanglutide targets India's growing diabetes and obesity crisis with an innovative drug.